University Of Michigan Rogel Cancer Center

This study tested whether adding the drug venetoclax to standard chemotherapy could help people with a hard-to-treat type of leukemia called secondary acute myeloid leukemia (sAML). The trial aimed to enroll 20 newly diagnosed patients but was stopped early after only 10 joined. …

This study looked at whether adding the drug rucaparib to the immunotherapy pembrolizumab could help keep stage IV non-small cell lung cancer from growing after initial treatment. It involved 25 adults whose cancer had not worsened after standard chemotherapy plus pembrolizumab. …

This study tested a combination of two drugs, ixazomib and romidepsin, in people with peripheral T-cell lymphoma that had come back or stopped responding to treatment. The trial was stopped early after only 11 participants enrolled, so the best dose could not be determined. The g…

This study tested whether adding the experimental drug CPI-613 to standard chemotherapy (gemcitabine and cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. About 75 participants were planned, but the trial was stopped early. The goa…

This study tested fezolinetant, a drug for hot flashes and night sweats, in women with breast cancer taking hormone therapy. The trial aimed to see if the drug could reduce the number and severity of these symptoms. Only 9 people took part before the study was stopped early.